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Mental health consequences of long term conflict
Survivors of chronic trauma need good mental health services and much more
Between 1969 and 2001, 3524 people were killed in 
civil disturbances in Northern Ireland. The annual 
death rate peaked at 479 in a population of 1.6 million. 
Deaths and injuries were unequally distributed, with 
people in working class urban communities and those 
living close to the Irish border being most at risk. Les-
sons can be learnt from such conflict, not only about 
the management of single episodes of psychological 
trauma but also about the effects of long term, violent 
divisions in society on mental health.
One of the aims of terrorism is to change attitudes 
and behaviours. This can lead to mental health prob-
lems in people who are targeted and in others. Prob-
lems include post-traumatic stress disorder, anxiety, 
depression, substance misuse, and (rarely) precipita-
tion of psychosis. Post-traumatic stress disorder can 
be treated by psychological treatments such as trauma 
focused cognitive behaviour therapy1 or antidepres-
sants.2 In this week’s BMJ, a randomised controlled 
trial by Duffy and colleagues assesses the effective-
ness of cognitive behaviour therapy in 58 people with 
chronic post-traumatic stress disorder associated with 
the conflict in Northern Ireland.3 It found that 12 
weeks of cognitive therapy significantly reduced the 
severity of post-traumatic stress disorder (mean differ-
ence on the post-traumatic stress diagnostic scale 9.6, 
95% confidence interval 3.6 to 15.6) and depression 
(mean difference on the Beck depression inventory 
10.1, 4.8 to 15.3), compared with being on a wait-
ing list. The authors note that response to treatment 
diminishes with time since the trauma and is poorer in 
people with a high level of depression at intake.3 The 
trial is the first to study cognitive behaviour therapy 
in the context of terrorism and other civil conflict and 
shows its efficacy.
Evidence from single traumatic events such as 
the 2001 terrorist attack on the Twin Towers in New 
York,4 the 2004 Madrid train bombings,5 and the 2005 
London transport bombings6 shows that most people 
directly affected do not develop serious psychiatric ill 
health. Where psychiatric ill health does follow it sub-
sides relatively quickly, with or without specific treat-
ment. Characteristics that affect reactions to trauma 
include previous exposure to trauma, availability of 
family support, and religious faith, but severe reactions 
are difficult to predict.6
At a time when the setting aside of armed conflict in 
Northern Ireland has been associated with consider- 
able political and economic developments, it might 
be expected that mental wellbeing would improve. 
However, mental health consequences of continued 
social divisions, residual violence, long term effects of 
conflict, and people’s difficulty in adapting to change 
persist.
The Northern Ireland health and social wellbeing survey 
(2001),7 completed three years after the ceasefire, found 
that 21% of people over 16 who had been affected by 
the conflict reported scores consistent with the presence 
of mental ill health. People who said they had been 
affected greatly were almost twice as likely to show signs 
of a possible mental health problem (34%) than those 
who said they had been affected only a little (18%).
In contrast to patterns elsewhere in Europe, suicide 
rates have risen in Northern Ireland, particularly 
among young socially marginalised men in areas 
closely identified with civil conflict.8 Experience in 
Israel indicates that conflict leads to high use of pri-
mary care and other services,9 and indeed Northern 
Ireland has higher rates of consultation and prescrip-
tion for a wide range of physical and mental ill health 
than elsewhere in the United Kingdom.
My experience is that people who have been active 
in violent conflict may cope well with the emotional 
consequences of what has been done to them and what 
they have done to others, as long as “the struggle” 
seems reasonable and justified.10 As the purpose of 
violent conflict becomes less clear, high rates of sub-
stance misuse, breakdown in relationships, and mood 
disorder follow, and the risk of suicide increases. The 
onset of frank psychiatric illness after chronic trauma 
may be delayed by many years. The mental health 
consequences for participants in civil conflict mirror 
those seen in military personnel after war.11
It is important to be sensitive about language when 
developing services for people affected by violence. 
The victim in one section of the community may 
be viewed as a perpetrator in another. The divisions 
between combatant and non-combatant may be 
unclear. Treatment services must be non-judgmental, 
person centred, and needs led. 
Clearly, health services alone cannot meet the 
needs of people affected by violence. The Bamford 
review (www.rmhldni.gov.uk/) of services in Northern 
Ireland considered policy and service provision for 
the province. It strongly advocated a whole systems 
approach to mental wellbeing, including teaching skills 
to increase resilience to trauma in schools while pro-
moting mental health through workplaces, faith com-
munities, arts facilities, and leisure services. Treatment 
services for mental ill health will be insufficient to meet 
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Preventing spinal cord injuries in rugby union
Other countries should follow New Zealand’s lead 
Spinal cord injuries were first identified as an impor-
tant sporting problem in the early and mid-1970s in 
rugby union,1 2 American (gridiron) football,3 and ice 
hockey.4 Subsequent studies have identified the most 
common mechanisms that cause these injuries.5 6 In 
some sports, such as American football, single mecha-
nisms that cause spinal injury, such as the spear tackle, 
have been identified,7 which has allowed effective pre-
ventive measures to be swiftly implemented (the spear 
tackle has now been banned in gridiron football).8 But 
in other sports progress in preventing spinal injury has 
been slow and difficult to measure.
In this week’s BMJ, a before and after study by Quarrie 
and colleagues assesses the effect of RugbySmart, a 
nationwide educational injury prevention programme, 
on the frequency of spinal cord injuries in New Zea-
land rugby union.9 It found that the introduction of 
the programme in 2001 coincided with a reduction 
in the number of spinal injuries (19 injuries were 
expected between 2001 and 2005 compared with eight 
reported). Furthermore, only one such injury occurred 
in the scrum, whereas nine were predicted. The data 
are robust as they originate from appropriately pro- 
cessed insurance claims. The authors conclude that 
their educational programme can decrease the rate at 
which serious spinal cord injuries occur in the scrum. 
Whether this intervention has the same effect in less 
controlled phases of the game—the tackle, ruck, and 
maul—remains unanswered.
To date, not a single complete data set for all spinal 
cord injuries has been reported in any major rugby 
union playing country, despite repeated calls for such 
information for the past 20 years.2 Without such data, 
the impact of spinal cord injuries and the effect of pre-
ventive measures in any rugby playing nation remains 
unknown. Regrettably, the number of these injuries in 
South Africa may not have decreased even 22 years 
after the problem was first identified.10
The study by Quarrie and colleagues provides a reason 
for renewed hope. The importance of the study is that 
it is unprecedented. Firstly, it shows that relevant data 
can be collected and used. Secondly, it establishes that 
at least some spinal cord injuries are preventable, as had 
previously been assumed.1 10 11 Thirdly, it sets the new 
standard. The study does have limitations though. It has 
a before and after design, which could be confounded by 
changes in the nature of the game or its players over the 
past five years that are unrelated to the introduction of 
the RugbySmart programme. A randomised controlled 
trial would have confirmed that the findings were not 
purely the result of a chance association.
Despite these limitations the results of the study are 
promising. Yet the study also highlights the need to do 
more; for example, to investigate other ways to prevent 
these injuries. These include training to improve neck 
strength and to enhance rugby related skills, increased 
medical supervision at matches, using protective gear, 
changes in the law, and continuing advocacy. Although 
the use of protective gear is actively enforced in certain 
sports,5 no such gear exists to prevent spinal cord injuries 
in rugby, and it may never do so. Changes in the law 
remain an option to reduce, for example, the possibility 
of vertex impact in front-on tackling. However, Quarrie 
and colleagues9 stress that although changes to the law 
can alter the way the game is played, such changes may 
not necessarily produce the desired outcomes.
All of the above methods for reducing injury are 
reasonable for developed countries whose players usu-
ally have sufficient access to quality training, coaching, 
and medical services. However, players in developing 
countries such as South Africa and Fiji,12 both of which 
have high rates of spinal cord injuries, are less likely to 
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people’s needs unless the context in which these needs 
arises is also considered. As yet government has been 
unable to secure the funding or workforce resources 
necessary to tackle the problem.
Policy makers and service planners throughout 
the world face challenges in prioritising services after 
conflict. It is tempting to believe that mental 
health needs diminish with the end of conflict. As 
international attention is diverted from the scene of 
conflict, society’s response to those affected must not 
be restricted to mental health services.
1	 	Tarrier	N,	Sommerfield	C,	Pilgram	H,	Humphreys	L.	Cognitive	therapy	
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have access to such services. Rectifying this remains a 
challenging objective in these countries.
Advocacy is the final important strategy. Quarrie and 
colleagues’ study would not have been possible if the 
New Zealand government did not provide a national 
insurance policy that also covers sports injuries. This 
raises the question of whether these injuries will ever 
be entirely preventable without the active support of 
national governments.
The beauty of the RugbySmart programme is that 
it can do no harm, and according to the results of this 
study may do great good. Given the relative infre-
quency of these injuries, a randomised controlled trial 
may be desirable but financially impractical. Wise 
rugby administrators should procrastinate no longer, 
awaiting the outcome of a definitive randomised con-
trolled trial. They should follow the lead of the New 
Zealand Rugby Union.
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Evaluation of hIV programmes
Independent national evaluations would mitigate global donors’ desire to claim 
sole success
The HIV implementers’ meeting in Kigali, Rwanda, 
16-19 June 2007, will bring together programme imple-
menters, researchers, representatives of donors who are 
funding HIV programmes, and international agencies 
tasked with controlling the global HIV epidemic. The 
meeting will focus on three initiatives that account for 
about 64% of international financing towards fighting 
HIV1—the Global Fund to Fight AIDS, TB, and Malaria; 
the President’s Emergency Plan for AIDS Relief; and 
the World Bank’s Multi-country AIDS Programme. The 
meeting aims to facilitate an open dialogue about the 
future direction of HIV programmes, and it will focus 
on identifying crucial barriers to and best practices in 
expanding efforts to control the epidemic.2
In this week’s BMJ, Reithinger and colleagues3 dis-
cuss the difficulties in evaluating the effectiveness of 
programmes to prevent transmission of HIV from 
mother to child. Difficulties include the inadequacy 
of current indicators used to monitor and evaluate 
operational programmes; weak health information 
systems, especially in the poorest countries of Africa 
which, for example, make it difficult to tell whether 
pregnant women who tested positive subsequently 
received treatment; and poor quality of interventions 
in terms of care offered and adherence to treatment. 
All of these challenges prevent reliable judgments 
being made about the impact of programmes.
The challenges are political as much as program-
matic. Global initiatives such as the President’s Emer-
gency Plan and the Global Fund have features, inherent 
in stand alone project approaches (rather than pooling 
of aid from different donors), which make them attrac-
tive to donors.4 5 They offer opportunities to channel 
funds into politically high profile areas, with short time 
frames that meet politicians’ needs. By focusing on 
disease specific interventions rather than on the health 
services needed to deliver them, donors can claim that 
improvements are the result of their contributions. 
Donors can demand reports in formats that meet their 
specific needs, which can mean that recipient countries 
have to prepare several reports in different formats for 
donors who are jointly funding programme activities. 
Also, constraints such as shortages of health workers 
and managers can often be overcome through financial 
incentives that attract scarce staff to well funded donor 
projects.
These features are generally associated with the 
President’s Emergency Plan. However, the Global 
Fund has shifted its approach in the past year and is 
attempting, with some success, to escape the shackles 
of the project approach. This is evident in its February 
2007 results report,1 in which it judges its own per-
formance according to five globally agreed commit-
ments6 and indicators of progress7 on making aid more 
effective—the need for country ownership; alignment, 
which means that donors will target countries’ priori-
ties and use countries’ management systems; harmo-
nisation of donor procedures and sharing of analyses; 
focusing on results at the country level; and mutual 
accountability.
The committee for the evaluation of the President’s 
Emergency Plan has also recently signed up to the 
need for improved harmonisation and coordination.8 
In some respects Global Fund, the President’s Emer-
gency Plan, and World Bank’s AIDS programme have 
out performed both stand alone project approaches 
and the pooling of aid from different donors, which 
several European donor agencies have championed. 
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They have disbursed money quickly, with high pro-      
portions—30% of Global Fund support1—reaching non-
governmental organisations that are central to the fight 
against HIV. The need to show accountability and per-       
formance is a requirement that these initiatives have 
grasped with enthusiasm, as in the Global Fund’s early 
mantra, “raise it, spend it, prove it.”
Plans for Global Fund’s five year evaluation (2007-8) 
are well advanced9; the World Bank will publish an 
evaluation of its AIDS programme at the Kigali meet-
ing; and the President’s Emergency Plan is planning a 
large scale evaluation. Global Fund and the President’s 
Emergency Plan both intend to provide evidence that 
the expansion in HIV control has reduced the inci-
dence of HIV, as well as morbidity and mortality from 
the disease. There has been an important shift in the 
language used by these initiatives, one that avoids ludi-
crous claims of being solely responsible for provid-
ing antiretroviral treatment to hundreds of thousands 
of patients. Both now use terms such as Global Fund 
(or the President’s Emergency Plan) supported pro-
grammes,1 8 reflecting the reality that multiple sources 
of funds, notably from recipient country governments 
and their populations, collectively support the expan-
sion of treatment.
The meeting in Rwanda next month will show 
whether or not the tensions that are inherent in donors’ 
need to claim successes, so as to generate sustainable 
long term funding, continue to undermine global 
efforts at coordination. The desire to avoid mutually 
destructive competition has led the Global Fund to 
declare that its five year evaluation (2007-8) will meas-
ure “contribution” rather than “attribution.”9 However, 
this should not detract from another pressing ques-
tion—not just whether the expansion is working—but 
how the collective efforts of all the global and national 
players, whether focused on diseases or on strengthen-
ing country systems, are working to support expansion 
and impact.10 Answering this question in the context 
of different countries means entering sensitive terrain. 
One solution would be for managers of national pro-
grammes and national AIDS councils to work with 
independently funded researchers, who will be less 
vulnerable to the pressures of attribution.
1	 	Global	Fund.	Partners in impact, results report. Geneva:	Global	Fund	
to	Fight	AIDS,	Tuberculosis	and	Malaria.	2007.	www.theglobalfund.
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3	 	Reithinger	R,	Megazzini	K,	Durako	SJ,	Harris	DR,	Vermund	SH.	
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to	child	transmission	of	HIV	in	Africa.	BMJ	2007	doi:	10.1136/
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J Int Dev	2003;15:67-86.
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editable?key=205.
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implementation: progress and promise.	Washington:	National	
Academies	Press,	2007.
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pdf.
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Drug resistant hIV
Promising research on three new drugs gives hope for chronically infected patients
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HIV has an impressive ability to replicate, mutate, 
and diversify, so developing drugs or vaccines that can 
fully contain the virus is a challenge. The only consist-
ently successful way to prevent replication of HIV is to 
administer a potent combination regimen that contains 
at least two and preferably three antiretroviral drugs. 
Fortunately, with more than 20 antiretroviral drugs 
currently available, it is easy to construct such regi-
mens for patients who are treatment naive.
However, a considerable number of patients have not 
had the chance to achieve full viral suppression despite 
access to antiretroviral drugs. These people are not well 
defined, but they generally began monotherapy with 
zidovudine in the early 1990s, and were sequentially 
exposed to each new drug as it became available. This 
sequential use of suboptimal regimens led to the emer-
gence of multidrug resistant HIV. These patients are 
often referred to as being in “deep salvage” and are at 
risk for disease progression.
This year, we may witness a dramatic shift in how 
these patients are managed.  For the first time in the 
HIV epidemic, three new agents have been developed 
for the management of drug resistant virus. They are 
the HIV integrase inhibitors, R5 inhibitors, and etra-
virine (TMC125)—a second generation non-nucleoside 
reverse transcriptase inhibitor. Hence, for patients in 
deep salvage, 2007 may be comparable to the land-
mark events of 1996, when the near miraculous effects 
of combination therapy were first observed. Although 
caution is needed given the hype that often surrounds 
any new treatment for HIV, it is nevertheless a time 
of renewed hope for such patients.
Most of the recent excitement has focused on HIV 
integrase inhibitors, a novel drug class that prevents 
integration of HIV DNA into the host genome.1 Two 
such drugs are actively being developed—raltegravir 
(MK-0518) and elvitegravir (GS-9137)—with the former 
now available in expanded access programmes. Interim 
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analyses from two ongoing phase III randomised 
double blind placebo controlled studies of raltegravir 
were recently presented at the 14th conference on retro-
viruses and opportunistic infections.2 3 A planned interim 
analysis at 16 weeks found that raltegravir was superior 
to placebo for reducing plasma HIV RNA to fewer than 
50 copies/ml (61% v 33%, P<0.001 in BENCHMRK-12; 
62% v 36%, P<0.001 in BENCHMRK-23). In a com-
bined analysis of both studies, patients who were not 
able to include another fully effective agent in their back-
ground regimen still benefited from raltegravir based 
treatment (at 16 weeks, 61% had a plasma HIV RNA 
below 400 copies/ml compared with 5% in the placebo 
group). Raltegravir was well tolerated in both studies.
Data on the second novel therapeutic drug class, 
the R5 inhibitors, were also presented at this confer-
ence. All strains of HIV enter CD4 positive T cells via 
the CCR5 or CXCR4 coreceptor.4 Most patients with 
early stage disease harbour viruses that enter via the 
CCR5 coreceptor, whereas up to half of those with 
advanced disease harbour at least some viruses that 
enter via the CXCR4 coreceptor.5 6 R5 inhibitors bind 
to the CCR5 molecule and prevent CCR5 utilising 
variants from entering cells.
Enthusiasm for this drug class had waned for several 
reasons. Firstly, many patients in deep salvage harbour 
viruses that use the CXCR4 and not the CCR5 co- 
receptor. Secondly, the use of an R5 inhibitor may 
force a virus to switch from a CCR5 utilising state to 
a potentially more pathogenic CXCR4 utilising state. 
Thirdly, unlike other antiretroviral drugs, R5 inhibitors 
target the host rather than the virus and might therefore 
be more toxic. Finally, one leading drug candidate was 
discontinued because of severe liver toxicity.7 
All of these concerns were at least partially addressed 
in two large phase IIb/III studies examining the role of 
the R5 inhibitor maraviroc in patients in deep salvage. 
A planned interim analysis at week 24 of MOTIVATE 
1 showed that maraviroc was superior to placebo 
for suppressing plasma HIV RNA to fewer than 50 
copies/ml (42.2% maraviroc once daily v 48.5% mara-
viroc twice daily v 24.6% placebo, P<0.001)8; similar 
findings were reported for MOTIVATE 2.9 The drug 
was well tolerated and no hepatic toxicity was seen. 
Moreover, although maraviroc did select for CXCR4 
utilising virus, this was not associated with a quicker 
short term decline in CD4 positive T cell numbers. 
Maraviroc received unanimous support from a Food 
and Drug Advisory (FDA) panel of outside experts on 
24 April 2007. 
The third agent that is also now available through 
expanded access programmes is etravirine (TMC125), 
a second generation non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) that appears to be active 
against virus that is resistant to the currently available 
NNRTIs (such as nevirapine and efavirenz). Results 
of a study of etravirine were reported last year.10 A 
randomised controlled trial in subjects with docu-
mented NNRTI resistance compared etravirine (400 
mg or 800 mg twice daily) with an investigator selected 
background versus a standard of care control regimen. 
At 48 weeks, the average reduction in HIV RNA was 
−0.88, −1.01, and −0.14 log10 copies/ml for the etra-
virine 400 mg, etravirine 800 mg, and control groups, 
respectively (P<0.05).
So will we see the end of deep salvage in 2007? 
Certainly not, because not all patients can achieve 
lifelong viral suppression for several reasons. Each of 
these drugs has the potential for significant drug-drug 
interactions, and it is not clear if they can be easily 
combined. Many patients harbour viruses that use the 
CXCR4 coreceptor and will not respond to maraviroc 
or other R5 inhibitors. Many patients treated with first 
generation NNRTIs have developed viruses that are 
cross resistant to etravirine (this is particularly true if 
the Y181C mutation is present).
Finally, it has always been challenging to translate 
data generated from a highly motivated study popula-
tion into real world situations. This may be especially 
true for the integrase inhibitors, as recent data sug-
gest that high level resistance to these drugs emerges 
rapidly. Despite these concerns, however, we will 
probably witness in the next year a remarkable trans-
formation in the prognosis of a generation of chroni-
cally ill, HIV infected adults, just as we saw in 1996 
with patients who were less treatment experienced.
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On 8 May 2007, a report by the international depart-
ment of the BMA entitled Improving health for the world’s 
poor: what can health professionals do? was launched at the 
House of Commons.1 It is the product of a four year 
collaboration between the BMA and the Department 
for International Development. The report comes hot 
on the heels of Lord Crisp’s report Global Health Partner-
ships: the UK contribution to health in developing countries,2 
endorsed by the prime minister and the secretaries 
of state for health and international development in 
February. It makes some aspirational statements, but 
health professionals looking for practical advice on 
how to offer their services to poor people in develop-
ing countries may be disappointed.
The report’s eight chapters cover health systems, 
water and sanitation, climate change, fair and ethical 
trade within the health system, malnutrition, tobacco 
control, public-private partnerships, and the 
World Health Organization. Each chapter 
concludes with recommendations on what 
the BMA and other organisations of health 
professionals can do in terms of advocacy 
and lobbying, but only chapters one and six 
have any recommendations for individual 
health workers. These include volunteering 
to work abroad, joining organisations that 
campaign for better health systems in poor 
countries, stopping smoking, and ensuring that their 
premises are smoke free.
Perhaps surprisingly, as the BMA has led the debate 
on healthcare rationing within the National Health 
Service, there is no discussion of which health interven-
tions are the most cost effective in developing coun-
tries. Some of the data given on the burden of disease 
in the developing world do not stand up to rigorous 
analysis. What are we to make, for example, of the 
statement that “until the onset of the millennium, effec-
tive treatments for 90% of the world’s global disease 
burden were generally unavailable?” We are told that 
the Department for International Development sees 
climate change as the most serious threat to develop-
ment and the achievement of the millennium develop-
ment goals. Can this really be true, given that the target 
date for achievement of these goals is 2015?
But perhaps the most surprising thing about this 
report is what is left out. Population growth is not 
mentioned as a threat to development. The chapter on 
malnutrition in Africa points out that food production 
has doubled in the past 40 years, but not that the popu-
lation of sub-Saharan Africa has increased from 225 
million to 751 million since 1960.3 The unmet need 
for family planning services in developing countries 
is surely something that health professionals can do 
something about. There is no mention of the vast and 
unmet need for mental health services in developing 
countries,4 the increasing toll of road traffic incidents 
and the lack of surgical services to deal with them,5 
or the lack of basic diagnostic laboratory services in 
many parts of the developing world.6 And no mention 
is made of the excellent work already being done in 
developing countries by thousands of health profes-
sionals from the United Kingdom working for non-
governmental organisations, mission hospitals, and 
government hospitals, or of those working in academic 
institutions doing research to develop better vaccines 
and treatments for the diseases of poverty.
Many young doctors and nurses in the UK want to 
work in developing countries. The Crisp report empha-
sised that exchange of health professionals between the 
NHS and developing countries is good for the NHS, 
good for developing countries, and good for the people 
who participate. Unfortunately, funds have not 
been made available to encourage cash 
strapped trusts to release medical staff to 
work overseas. Moreover, in the past year 
three barriers have come into force that 
will prevent this exchange from happen-
ing, as pointed out in a recent editorial in 
the BMJ.7 Firstly, doctors from developing 
countries can no longer train in the NHS if 
there is a European applicant for the post 
they apply for. Secondly, junior doctors in 
the UK will find it increasingly difficult to get time out 
from the rigid training programmes imposed by Mod-
ernising Medical Careers. Thirdly, the lack of clarity 
about revalidation after working overseas is an added 
deterrent. Lord Walton asked the panel at the launch 
of the BMA’s report what the government was doing 
to make it easier for junior doctors to work overseas, 
but no one from the Department of Health was there 
to answer his question.
Health professionals from the UK have a long and 
honourable tradition of service to poor people in devel-
oping countries. It would be a pity if, as a result of the 
difficulties created by the Department of Health, the 
best advice the BMA can give to doctors who want to 
help the world’s poor is to join the BMA and ensure 
that their surgeries are smoke free and carbon neutral.
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